Advertisement

Topics

Verastem Sees Phase III Success With PIK3 Inhibitor Dropped By AbbVie

13:57 EDT 6 Sep 2017 | SCRIP

Duvelisib, licensed from Infinity in 2016, reduces risk of disease progression or death compared to Arzerra in a Phase III...

      

Related Stories

 

Original Article: Verastem Sees Phase III Success With PIK3 Inhibitor Dropped By AbbVie

NEXT ARTICLE

More From BioPortfolio on "Verastem Sees Phase III Success With PIK3 Inhibitor Dropped By AbbVie"

Quick Search
Advertisement
 

Relevant Topic

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...